Economic value of anti-CD20 therapies in multiple sclerosis: a systematic review of cost-effectiveness studies
Therapeutic Advances in Neurological Disorders
Published online on March 29, 2026
Abstract
Therapeutic Advances in Neurological Disorders, Volume 19, January-December 2026.
Background:Disease-modifying therapies (DMTs) have transformed multiple sclerosis (MS) care but are associated with substantial costs. Among high-efficacy DMTs, anti-CD20 antibodies are widely used, yet their economic value, particularly compared with ...
Background:Disease-modifying therapies (DMTs) have transformed multiple sclerosis (MS) care but are associated with substantial costs. Among high-efficacy DMTs, anti-CD20 antibodies are widely used, yet their economic value, particularly compared with ...